Have a feature idea you'd love to see implemented?
Let us know!
IBRX ImmunityBio Inc
Price (delayed)
$2.32
Market cap
$1.62B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.9
Enterprise value
$2.52B
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer
Highlights
ImmunityBio's EPS has increased by 14% YoY and by 7% QoQ
ImmunityBio's quick ratio has decreased by 37% from the previous quarter but it has increased by 4.2% YoY
ImmunityBio's equity has shrunk by 81% YoY and by 7% QoQ
The debt rose by 42% year-on-year
Key stats
What are the main financial stats of IBRX
Market
Valuations
Earnings
Shares outstanding
696.83M
Market cap
$1.62B
Enterprise value
$2.52B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
220.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
343.87
Revenue
$7.33M
Gross profit
$7.33M
Net income
-$587.79M
EBIT
-$438.96M
EBITDA
-$415.51M
Free cash flow
-$434.1M
Per share
Balance sheet
Liquidity
EPS
-$0.9
EPS diluted
-$0.92
Free cash flow per share
-$0.62
Book value per share
-$1.07
Revenue per share
$0.01
TBVPS
$0.5
Total assets
$364.57M
Total liabilities
$1.11B
Debt
$1.02B
Equity
-$745.15M
Working capital
$102.19M
Debt to equity
-1.36
Current ratio
2.68
Quick ratio
2.22
Net debt/EBITDA
-2.18
Margins
Efficiency
Dividend
EBITDA margin
-5,667%
Gross margin
100%
Net margin
-8,016.8%
Operating margin
-4,912.3%
Return on assets
-137.2%
Return on equity
N/A
Return on invested capital
-38.5%
Return on capital employed
-144.6%
Return on sales
-5,986.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IBRX stock price
How has the ImmunityBio stock price performed over time
Intraday
-6.45%
1 week
-15.02%
1 month
-19.16%
1 year
-39.74%
YTD
-9.38%
QTD
-9.38%
Financial performance
How have ImmunityBio's revenue and profit performed over time
Revenue
$7.33M
Gross profit
$7.33M
Operating income
-$360.17M
Net income
-$587.79M
Gross margin
100%
Net margin
-8,016.8%
ImmunityBio's operating margin has soared by 92% YoY and by 82% from the previous quarter
The net margin has surged by 90% year-on-year and by 82% since the previous quarter
ImmunityBio's net income has decreased by 28% YoY
Growth
What is ImmunityBio's growth rate over time
Valuation
What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
220.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
343.87
ImmunityBio's EPS has increased by 14% YoY and by 7% QoQ
ImmunityBio's equity has shrunk by 81% YoY and by 7% QoQ
The P/S is 96% less than the last 4 quarters average of 4935.3 and 95% less than the 5-year quarterly average of 4889.6
Efficiency
How efficient is ImmunityBio business performance
ImmunityBio's return on sales has surged by 90% YoY and by 83% QoQ
The company's return on invested capital rose by 36% YoY and by 10% QoQ
IBRX's return on assets is down by 7% year-on-year and by 2.2% since the previous quarter
Dividends
What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IBRX.
Financial health
How did ImmunityBio financials performed over time
The total assets is 67% less than the total liabilities
ImmunityBio's quick ratio has decreased by 37% from the previous quarter but it has increased by 4.2% YoY
ImmunityBio's total liabilities has increased by 32% YoY but it has decreased by 2.9% from the previous quarter
ImmunityBio's equity has shrunk by 81% YoY and by 7% QoQ
The debt rose by 42% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.